Canaccord Genuity Maintains Bioventus at Buy, Lowers Price Target to $18
Canaccord Genuity has maintained its 'Buy' rating on Bioventus Inc. while adjusting its 12-month price target from $19 to $18.
Stocks · News reference
Analysts have updated the 12-month price target for Bioventus Inc. to $17.40, representing a potential upside of 32%.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Canaccord Genuity has maintained its 'Buy' rating on Bioventus Inc. while adjusting its 12-month price target from $19 to $18.
Bioventus Inc. announced its financial results for the third quarter of 2026, reporting $142.4 million in revenue and $0.17 in non-GAAP earnings per diluted share.
Filed: 2026-11-02 AccNo: 0001665988-26-000050 Size: 838 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Bioventus Inc. has announced it will release its financial results for the third quarter of fiscal year 2026 after the market closes on November 2, 2026.
Bioventus Inc. announced it will report third quarter fiscal year 2026 financial results on November 2, 2026 after market close, with a management conference call at 4:30 p.m. ET to discuss results and provide a business update. The webcast will be available on the company's investor relations website.
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.